Table 4.
Changes in the distributions of diagnoses between each PALF among the 10 sites participating in all phases of PALF.
| Characteristic | All Participants (n= 1144) | Sites in all 3 phases Total (N=658) | Phases 1 & 2 12/99–12/10 (N=515) | Phase 3 5/12 – 12/14 (N=143) | Phase comparison p-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Final Diagnosis, n % | 0.002* | ||||||||
| Indeterminate | 491 | 42.9 | 291 | 44.2 | 247 | 48.0 | 44 | 30.8 | |
| APAP | 152 | 13.3 | 91 | 13.8 | 67 | 13.0 | 24 | 16.8 | |
| AutoAB(+)/Autoimmune | 75 | 6.6 | 39 | 5.9 | 33 | 6.4 | 6 | 4.2 | |
| Metabolic | |||||||||
| Wilson Disease | 36 | 3.2 | 21 | 3.2 | 21 | 4.1 | 0 | 0.0 | |
| Mitochondrial Disease | 17 | 1.5 | 9 | 1.4 | 4 | 0.8 | 5 | 3.5 | |
| Galactosemia | 15 | 1.3 | 6 | 0.9 | 4 | 0.8 | 2 | 1.4 | |
| Other Metabolic | 42 | 3.7 | 19 | 2.9 | 17 | 3.3 | 2 | 1.4 | |
| Non-APAP drug | 37 | 3.2 | 24 | 3.7 | 17 | 3.3 | 7 | 4.9 | |
| Gestational alloimmune liver disease | 37 | 3.2 | 21 | 3.2 | 13 | 2.5 | 8 | 5.6 | |
| Viral | |||||||||
| Herpes/Enterovirus | 53 | 4.6 | 31 | 4.7 | 18 | 3.5 | 13 | 9.1 | |
| Other Viral | 43 | 3.8 | 20 | 3.0 | 15 | 2.9 | 5 | 3.5 | |
| Hemophagocytic lymphohistiocytosis | 34 | 3.0 | 24 | 3.6 | 15 | 2.9 | 9 | 6.3 | |
| Shock/Ischemia | 40 | 3.5 | 26 | 4.0 | 17 | 3.3 | 9 | 6.3 | |
| Other | 72 | 6.3 | 36 | 5.5 | 27 | 5.2 | 9 | 6.3 | |
| Indeterminate Final Diagnosis | 491 | 42.9 | 291 | 44.2 | 247 | 48.0 | 44 | 30.8 | 0.0003 |
*
p-value for final diagnoses listed in bold